Quantcast

Latest Protease inhibitor Stories

2009-11-03 07:15:00

BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc (Nasdaq: VRUS) and InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus (HCV).(i) The study, conducted by Roche as part of its collaborations with InterMune and Pharmasset, combined the...

2009-10-29 15:01:00

BRISBANE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 4, 2009 at 3:20 p.m. EST. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company...

2009-10-16 09:17:00

NEW YORK, Oct. 16 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Competitor Analysis: Targeted Therapy of Hepatitis C http://www.reportlinker.com/p0154666/Reportlinker-Adds-Competitor-Analysis-Targeted-Therapy-of-Hepatitis-C.html Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted...

2009-10-01 06:00:00

BRISBANE, Calif., Oct. 1 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Fourth Annual JMP Securities Healthcare Focus Conference in New York on October 5, 2009 at 3:30 p.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com....

2009-09-08 15:58:00

U.S. and Japanese scientists using mice say they have successfully restored normal levels of a key protein involved in the rare brain disorder lissencephaly. The University of California-San Francisco scientists said they used protease inhibitors to achieve the restoration of the protein, a reduction of which causes lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants. The researchers said their accomplishment...

2009-09-07 06:43:08

UCSF researchers have successfully used protease inhibitors to restore to normal levels a key protein involved in early brain development. Reduced levels of that protein have been shown to cause the rare brain disorder lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants. The findings offer a proof-of-principle, at least in mice, that the genetic equivalent to human lissencephaly, also known as "smooth brain"...

2009-08-10 07:30:00

PALO ALTO, Calif., Aug. 10, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon. CLEAN-1 will evaluate the safety and antiviral...

2009-08-07 06:00:00

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Canaccord Adams 29th Annual Global Growth Conference in Boston on August 12, 2009 at 10:30 a.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The...

2009-07-30 15:05:00

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and ribavirin in hepatitis C patients. Allowance of the protocol has been received from the United States Food and Drug Administration (FDA), and patient dosing is expected to commence within the next several weeks. In the Phase II study, naive genotype 1 patients...

2009-07-20 15:05:00

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has successfully completed a three-day proof-of-concept study of IDX184. Idenix is developing IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. This double-blind, placebo-controlled, monotherapy,...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related